Elicio Therapeutics, Inc. (ELTX): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:03 ET
- Event date
- 2026-11-13
- Accession no.
- 0001601485-26-000070
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Elicio Therapeutics reports director elections and auditor ratification
At its November 12, 2026 annual meeting, Elicio Therapeutics stockholders elected Julian Adams, Jay R. Venkatesan and Carol Ashe as Class III directors to serve until the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Both proposals received the necessary votes for adoption.
- The annual meeting was held on November 12, 2026.
- Julian Adams, Ph.D., Jay R. Venkatesan, M.D., and Carol Ashe were elected to serve until the 2029 annual meeting.
- Stockholders ratified Baker Tilly US, LLP for the fiscal year ending December 31, 2026.
- Holders of 18,081,914 shares voted, representing 66.74% of voting power and constituting a quorum.
shareholder voteboard change
Items reported
- Item 5.07: Submission of Matters to a Vote of Security Holders
The company reports the results of a shareholder meeting: each matter voted on and the votes cast for, against, abstaining and broker non-votes.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | eltx-20261113.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.